BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27481952)

  • 1. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing New Antibacterial Drug Development for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia.
    Toerner JG; Rubin D
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S37-8. PubMed ID: 27481951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
    Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials.
    Bart SM; Rubin D; Kim P; Farley JJ; Nambiar S
    Clin Infect Dis; 2021 Aug; 73(3):e602-e608. PubMed ID: 33173946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
    Stergiopoulos S; Calvert SB; Brown CA; Awatin J; Tenaerts P; Holland TL; DiMasi JA; Getz KA
    Clin Infect Dis; 2018 Jan; 66(1):72-80. PubMed ID: 29020279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.
    Ericson JE; McGuire J; Michaels MG; Schwarz A; Frenck R; Deville JG; Agarwal S; Bressler AM; Gao J; Spears T; Benjamin DK; Smith PB; Bradley JS;
    Pediatr Infect Dis J; 2020 Aug; 39(8):658-664. PubMed ID: 32150005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
    Weiss E; Zahar JR; Alder J; Asehnoune K; Bassetti M; Bonten MJM; Chastre J; De Waele J; Dimopoulos G; Eggimann P; Engelhardt M; Ewig S; Kollef M; Lipman J; Luna C; Martin-Loeches I; Pagani L; Palmer LB; Papazian L; Poulakou G; Prokocimer P; Rello J; Rex JH; Shorr AF; Talbot GH; Thamlikitkul V; Torres A; Wunderink RG; Timsit JF
    Clin Infect Dis; 2019 Nov; 69(11):1912-1918. PubMed ID: 30722013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia.
    Talbot GH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S144-9. PubMed ID: 20597665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
    Jones RN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S81-7. PubMed ID: 20597676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Talbot GH; Das A; Cush S; Dane A; Wible M; Echols R; Torres A; Cammarata S; Rex JH; Powers JH; Fleming T; Loutit J; Hoffmann S;
    J Infect Dis; 2019 Apr; 219(10):1536-1544. PubMed ID: 30649434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
    Kidd JM; Kuti JL; Nicolau DP
    Expert Opin Pharmacother; 2018 Mar; 19(4):397-408. PubMed ID: 29411661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Bader JC; Lakota EA; Dale GE; Sader HS; Rex JH; Ambrose PG; Bhavnani SM
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Public-Private Collaborations Are Driving Solutions to the Antibacterial Drug Development Crisis.
    Madre L; Tenaerts P
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S25-6. PubMed ID: 27481948
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
    Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
    Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
    Barriere SL
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
    Kinamon T; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans SR; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW; Gopinath R
    Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38527855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hospital-acquired or ventilator-associated bacterial pneumonia.
    Puzniak L; Dillon R; Lodise T
    PLoS One; 2023; 18(1):e0279844. PubMed ID: 36598902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials.
    Rotstein C; Lynch JP; Zhanel GG
    Expert Rev Anti Infect Ther; 2023 Oct; ():1-13. PubMed ID: 37811572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Powers JH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1(Suppl 1):S18-28. PubMed ID: 20597667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.